Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 43

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Systemic lupus erythematosus

Recruiting

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Cardiac amyloidosis

Recruiting

Study on the Effects of Dobutamine on Heart Function in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Dobutamine
  • Sponsor:Region Midtjylland

Systemic lupus erythematosus

Recruiting

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Atopic keratoconjunctivitis

Recruiting

Study on Ciclosporin for Treating Atopic Keratoconjunctivitis in Adults

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Rigshospitalet

Myasthenia gravis

Recruiting

Study on the Long-Term Safety of Zilucoplan in Children with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Zilucoplan
  • Sponsor:UCB Biopharma

Chronic cutaneous lupus erythematosus+2

Recruiting

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Dermatomyositis+2

Recruiting

Study on Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Cholangitis sclerosing

Recruiting

Study of Oral Vancomycin for Adults and Young Adults with Primary Sclerosing Cholangitis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vancomycin
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Crohn's disease

Recruiting

Study Comparing Vedolizumab and Adalimumab for Crohn's Disease Patients Who No Longer Respond to Adalimumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Type 1 diabetes mellitus

Recruiting

Study on Anti-T Lymphocyte Immunoglobulin for Children and Young Adults with Recent Type 1 Diabetes to Preserve Beta Cell Function

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit
  • Sponsor:Institute For Clinical And Experimental Medicine

Crohn's disease

Recruiting

Study on Crohn's Disease: Evaluating Risankizumab's Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

ABO haemolytic disease of newborn

Recruiting

Study of Nipocalimab in Pregnant Women at Risk of Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.